@prefix nalt: <https://lod.nal.usda.gov/nalt/> .
@prefix skos: <http://www.w3.org/2004/02/skos/core#> .
@prefix dc: <http://purl.org/dc/terms/> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix ns0: <https://lod.nal.usda.gov/naltv#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .

nalt:228984
  skos:prefLabel "inhibidores de la enzima convertidora de angiotensina"@es, "angiotensin-converting enzyme inhibitors"@en ;
  skos:hiddenLabel "(ACE) inhibitors"@en, "angiotensin-converting-enzyme inhibitor"@en, "angiotensin I converting enzyme inhibitors"@en, "angiotensin converting enzyme inhibitors"@en, "kininase II inhibitor"@en, "ACE-inhibitor"@en, "angiotensin converting enzyme (ACE) inhibitors"@en, "angiotensin-converting-enzyme inhibitors"@en, "angiotensin I converting enzyme inhibitor"@en, "angiotensin-converting enzyme inhibitor"@en, "ACE-inhibitors"@en, "angiotensin converting enzyme (ACE) inhibitor"@en, "(ACE) inhibitor"@en, "angiotensin I-converting enzyme inhibitor"@en ;
  dc:modified "2020-04-14"^^xsd:date ;
  skos:altLabel "kininase II inhibitors"@en, "kininase II antagonists"@en, "ACE inhibitors"@en, "angiotensin I-converting enzyme inhibitors"@en ;
  skos:related nalt:126802 ;
  skos:definition nalt:228984_def ;
  a skos:Concept, <https://lod.nal.usda.gov/naltv#Chemical> ;
  skos:inScheme <https://lod.nal.usda.gov/nalt> ;
  ns0:marc001 "63030" ;
  skos:broader nalt:19023 ;
  dc:created "2014-09-17"^^xsd:date .

nalt:126802
  skos:prefLabel "peptidil-dipeptidasa A"@es, "peptidyl-dipeptidase A"@en ;
  a ns0:Chemical, skos:Concept ;
  skos:related nalt:228984 .

nalt:19023
  skos:prefLabel "inhibidores de proteinasa"@es, "proteinase inhibitors"@en ;
  a ns0:Chemical, skos:Concept ;
  skos:narrower nalt:228984 .

ns0:Chemical
  rdfs:label "Chemical"@en ;
  a owl:Class .

nalt:228984_def
  rdf:value "Fármacos cuya principal indicación es el tratamiento de la hipertensión y la insuficiencia cardíaca. Ejercen un efecto hemodinámico principalmente mediante la inhibición del sistema renina-angiotensina. Además, modulan la actividad del sistema nervioso simpático e incrementan la síntesis de la prostaglandina. Ante todo, producen vasodilatación y una suave natriuresis, sin afectar el ritmo ni la contractilidad cardíacos."@es, "A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility."@en ;
  dc:source "Medical Subject Headings" ;
  a ns0:Definition .

<https://lod.nal.usda.gov/nalt>
  rdfs:label "NALT Full"@en ;
  a skos:ConceptScheme .